Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD | MicrobiomeTrials← Back to trialsNCT06997965
Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2026-04-20Est. Completion: 2027-09-01
Enrollment target: 60 participants Locations- Digestive & Liver Center of Florida, Orlando, Florida, United States
- Velocity Clinical- Salt Lake City, Salt Lake City, Utah, United States
- GI Institute Research Foundation, Vancouver, British Columbia, Canada
- London Digestive Disease Institute, London, Ontario, Canada
- The Office of Dr. Jason Reinglas, Scarborough Village, Ontario, Canada
Other microbiome trials you might be interested in
Fistula in AnoCrohn Disease
Crohn's disease is a chronic inflammatory condition that can affect any part of the bowel which can be controlled by a c…
Multiple LocationsCompleted Jun 11, 2026
Inflammatory Bowel DiseaseCrohn's DiseaseUlcerative Colitis
Background:
Inflammatory bowel disease (IBD) is a term used to describe disorders that cause long-term inflammation in …
Bethesda, United StatesEst. completion Jun 1, 2036
Recruiting
Ulcerative ColitisCrohn's Disease
More older people (more than 65 years of age) around the world are getting Ulcerative Colitis (UC) or Crohn's Disease (C…
Cambridge, United StatesEst. completion Dec 15, 2026